Overview

Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer

Status:
Unknown status
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
A single institution study to evaluate the safety and tolerability of the combination treatment of nivolumab, ipilimumab, CMP-001 and radiosurgery in patients with metastatic colorectal cancer with liver metastases.
Phase:
Phase 1
Details
Lead Sponsor:
Sheba Medical Center
Collaborators:
Bristol-Myers Squibb
Checkmate Pharmaceuticals
Treatments:
Antibodies, Monoclonal
Ipilimumab
Liver Extracts
Nivolumab